Replimune Group (NASDAQ:REPL) Stock Price Down 4.8% on Insider Selling

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded down 4.8% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $22.22 and last traded at $22.1740. Approximately 1,743,679 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 4,312,275 shares. The stock had previously closed at $23.28.

Specifically, Director Joseph P. Slattery sold 5,200 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the completion of the sale, the director directly owned 1,467 shares of the company’s stock, valued at approximately $31,980.60. This trade represents a 78.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Friday, August 7th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 6.90. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -7.94 and a beta of 0.93. The stock’s 50-day moving average is $14.39 and its 200 day moving average is $9.82.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. As a group, analysts predict that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.

Institutional Trading of Replimune Group

Hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $99,171,000. Montanova Capital LLC grew its holdings in Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after acquiring an additional 168,000 shares during the period. Opaleye Management Inc. acquired a new position in Replimune Group during the second quarter worth $15,332,000. Dimensional Fund Advisors LP grew its holdings in Replimune Group by 1.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after acquiring an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC purchased a new position in Replimune Group in the first quarter worth $7,650,000. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.